SEC Form 4 · accession 0000899243-19-000527
Dianthus Therapeutics, Inc. /DE/ · DNTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Ryan
Officer — See Remarks
Period of report
Jan 2, 2019
Accepted (ET)
Jan 4, 2019 · 4:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001690585
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.00 | Jan 2, 2019 | A | 329,379 | A | — | Jan 1, 2029 | Common Stock | 329,379 | 329,379 | D |
Explanation of responses
- F1This option shall vest and become exerciseable over four years, with 25% of this option vesting on January 1, 2020, and the remainder vesting in 36 equal monthly installments thereafter.
Remarks
Chief Operating and Financial Officer